Featured Stories
Allergan Acquiesces To Activist Appaloosa With CEO-Chairman Role Split, But Not Yet
Allergan will split the CEO and chairman roles as requested by Appaloosa, but only in the next leadership transition. The activist shareholder fired back with renewed opposition to leaving Brent Saunders in both top jobs.
Novartis’ Srinivasan On Putting Data Analytics To Use In Clinical Development
Badhri Srinivasan, head of global development operations at Novartis, outlines in an interview with Scrip the company’s efforts towards making clinical trials more efficient and decentralized, and how the Nerve Live data analytics platform is helping minimize non-performing sites.
Signs Of Change? Lilly, Merck, Janssen Report Slowing List Price Growth In 2018
Annual transparency reports from the three firms show US price increases continued, though less aggressively, and net prices declined for Lilly and Janssen.
Latest News
Recent Tweets from ScripGETTING IT RIGHT – Drawing Together Key Stakeholders To Shape The Real-World Data Revolution
This special report reveals the challenges and solutions for early payer involvement in real-world data clinical trials, as discussed by industry leaders at a recent roundtable.
Commercial Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Scandinavia Serves Up Two Partners For Alexion, In Its Rare Disease Sweet-Spot
Leading US biotech Alexion is to collaborate with two European biotechs, Affibody and Zealand, on early-stage products for rare diseases, involving bivalent antibody-mimetic scaffolds and novel peptides.
What Brexit Effect? UK Biotech Start-Ups Reach Record Numbers
With UK biotech venture capital investment at its highest level to date, biotech company building is showing no let up, with almost half of all UK biotech companies formed within the last three years.
Aimmune Lays Foundations In Europe For Lead Peanut Allergy Therapeutic
With Aimmune’s AR101 oral immunotherapeutic nearing the market in the EU and US, the company sketches out its European business strategy after ARTEMIS meets its primary endpoint.
Finance Watch: Flagship Raises $824m To Speed Growth Of Its Portfolio Companies
Private Company Edition: The VC firm and start-up factory Flagship Pioneering brings in new cash for existing investments, tapping into investors eager to back "big, bold platform ideas" in the life sciences. Also, new financings include $100m-plus deals for Harmony and Beam.
Alios Buy Best Forgotten For Johnson & Johnson As RSV Failure Costs It Dear
Johnson & Johnson has written off a further $700m against the RSV asset that it obtained with its $1.75bn purchase of Alios.
Adios To Alcon In April As Novartis Confirms Spin-Off Date
With the eye-care business set for its own stock exchange listings next month and the future of Sandoz the subject of much discussion, Novartis' plan to be a pure play pharma firm moves ever closer.
How One Startup Plans To Win Primary Care Battle In China
Millions of people lack access to quality healthcare services and products in China, but now one company has raised millions in funding and vows to harness the power of the internet to get temperature-controlled drugs and quality diagnostic services to everyone who needs them.
Asia Deal Watch: Zogenix Partners Japanese Rights To Pediatric Epilepsy Therapy To Nippon Shinyaku
Nippon Shinyaku obtains rights to sell Dravet and Lennox-Gastaut syndrome drug Fintepla in its home market. Sun Pharma increases its ownership stake in Russia’s PJSC Biosintez.
Policy & Regulation Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
AZ's Forxiga Gets Type 1 Diabetes EU Okay As Sanofi Suffers US Setback
Forxiga is the first oral medicine approved in the EU as an adjunct to insulin for type 1 diabetes and the regulatory boost for AstraZeneca comes as Sanofi gets a CRL from the FDA for Zynquista.
Bluebird’s Gene Therapy LentiGlobin Coming Into Land In The EU?
Two charities say a positive CHMP opinion has been given to bluebird bio’s transfusion-dependent β-thalassemia gene therapy LentiGlobin at the first meeting of the EMA’s scientific committee at its new home in Amsterdam.
Dong-A Vows Legal Steps As Korea Imposes Heavy Penalties Over Rebates
Korea temporarily suspends reimbursement of drugs involved in Dong-A ST’s alleged illegal rebate payments to doctors, raising concerns from the industry whether the new measures are appropriate. The company concedes it violated the Pharmaceutical Affairs Act but vows to seek legal redress as it claims there are substantial issues with the punitive measures.
Finance Watch: Panic Over FDA Commissioner's Resignation Was Short-Lived, Though IPOs Still Languish
Public Company Edition: Biotech stocks sank when US FDA Commissioner Scott Gottlieb announced his departure, but have nearly recovered to pre-resignation levels, except for newly public firms. Also, Biohaven's raises cash for PRV purchase and Endo issues $1.5bn in new debt.
Research & Development Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Proteostasis Puts Best Face On Unspectacular CF Combo Data
With data showing a lung function and sweat chloride benefit for its proprietary CFTR-modulating triplet, Proteostasis says it’s moving ahead. But analysts and investors are concerned the effects are less than seen with Vertex drugs.
Aimmune Lays Foundations In Europe For Lead Peanut Allergy Therapeutic
With Aimmune’s AR101 oral immunotherapeutic nearing the market in the EU and US, the company sketches out its European business strategy after ARTEMIS meets its primary endpoint.
Otsuka’s Avanir Encouraged By First Peek At Treatment For Alzheimer’s Agitation
Phase III results from Avanir’s candidate for agitation in patients with Alzheimer’s disease offers some hope in a setting for which there is no specific treatment.
Pipeline Watch: Phase III Readouts For Vibegron, Doria And Ameluz
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.